Cantillo, E., Zemla, T., Moroney, J., Alvarez, E., Yauch, L., Lin, Y., … Slomovitz, B. (2022). TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC). In E-Posters (Trials In Progress) (p. A227.3-A228). BMJ Publishing Group Ltd. https://doi.org/10.1136/ijgc-2022-igcs.519

Cantillo, Evelyn, Tyler Zemla, John Moroney, Edwin Alvarez, Lauren Yauch, Yvonne Lin, Michelle Brockman, et al. “TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC).” In E-Posters (Trials In Progress), A227.3-A228. BMJ Publishing Group Ltd, 2022. https://doi.org/10.1136/ijgc-2022-igcs.519.

Cantillo E, Zemla T, Moroney J, Alvarez E, Yauch L, Lin Y, et al. TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC). In: E-Posters (Trials In Progress). BMJ Publishing Group Ltd; 2022. p. A227.3-A228.

Cantillo, Evelyn, et al. “TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC).” E-Posters (Trials In Progress), BMJ Publishing Group Ltd, 2022, p. A227.3-A228. Crossref, doi:10.1136/ijgc-2022-igcs.519.

Cantillo E, Zemla T, Moroney J, Alvarez E, Yauch L, Lin Y, Brockman M, Dilallo G, Liu J, Secord AA, Nixon A, Mandrekar S, Matulonis U, Kozono D, Slomovitz B. TP010/#242 AFT-50 EndoMAP: a phase IB/II multicohort study of targeted agents with atezolizumab (ATEZO) for patients (PTS) with recurrent or persistent endometrial cancer (EC). E-Posters (Trials In Progress). BMJ Publishing Group Ltd; 2022. p. A227.3-A228.